US · ISRG · MEDICAL - INSTRUMENTS & SUPPLIES
Intuitive Surgical, Inc. (ISRG) intrinsic value and stock valuation
$399.05as of 2026-11-21 · Mkt cap 132.55B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Intuitive Surgical, Inc. DCF and intrinsic value
InvestorsCraft values ISRG with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ISRG’s statements →
Intuitive Surgical, Inc. Graham Number
Graham Number: $95.14d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Becton, Dickinson and Company (BDX) $212.78
- ResMed Inc. (RMD) $235.63
- West Pharmaceutical Services, Inc. (WST) $390.30
- The Cooper Companies, Inc. (COO) $58.88
- Baxter International Inc. (BAX) $25.39
- Repligen Corporation (RGEN) $163.81
- Teleflex Incorporated (TFX) $161.58
- Merit Medical Systems, Inc. (MMSI) $84.34
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.1B | $8.35B | $7.12B | $6.22B | $5.71B |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B |
| Net income | $2.86B | $2.32B | $1.8B | $1.32B | $1.7B |
| EPSd | $7.87M | $6.42M | $5.03M | $3.65M | $4.66M |
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Capital expenditure | -$-539.8M | -$-1.11B | -$-1.06B | -$-532.4M | -$-353.5M |
| Free cash flow | $2.49B | $1.3B | $749.6M | $958.4M | $1.74B |
| Total assets | $20.6B | $18.8B | $15.4B | $13B | $13.6B |
| Total debt | $302.8M | $146M | $0.00 | $0.00 | $87M |
| Net debt | -$-3.07B | -$-1.88B | -$-2.75B | -$-1.58B | -$-1.2B |
| Total equity | $17.9B | $16.5B | $13.4B | $11.1B | $12B |
| Cash and short-term investments | $5.93B | $4.01B | $5.22B | $4.12B | $4.23B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.1B | $8.35B | $7.12B | $6.22B | $5.71B |
| Cost of revenue | $3.42B | $2.72B | $2.39B | $2.03B | $1.75B |
| Gross profit | $6.64B | $5.63B | $4.73B | $4.2B | $3.96B |
| Research and development expenses | $1.31B | $1.15B | $998.8M | $879M | $671M |
| Selling, general and administrative expenses | $2.39B | $2.14B | $1.96B | $1.74B | $1.47B |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $3.7B | $3.29B | $2.96B | $2.62B | $2.14B |
| Cost and expenses | $7.12B | $6B | $5.36B | $4.65B | $3.89B |
| Interest income | $365.9M | $324.9M | $192.1M | $29.7M | $69.3M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $677.1M | $462M | $402.2M | $365.8M | $317M |
| Ebitda | $3.99B | $3.14B | $2.36B | $1.97B | $2.21B |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B |
| Total other income/expenses, net | $365.9M | $324.9M | $192.1M | $29.7M | $69.3M |
| Income before tax | $3.31B | $2.67B | $1.96B | $1.61B | $1.89B |
| Income tax expense | $434.8M | $336.3M | $141.6M | $262.4M | $162.2M |
| Net income | $2.86B | $2.32B | $1.8B | $1.32B | $1.7B |
| Weighted average shares outstanding | $356.9M | $355.2M | $351.2M | $355.7M | $356.1M |
| Weighted average diluted shares outstanding | $362.7M | $362M | $357.4M | $362M | $365.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.93B | $4.01B | $5.22B | $4.12B | $4.23B |
| Net receivables | $1.63B | $1.36B | $1.27B | $1.07B | $893M |
| Inventory | $1.84B | $1.49B | $1.22B | $893.2M | $587.1M |
| Total current assets | $9.78B | $7.11B | $7.89B | $6.25B | $5.84B |
| Property, plant and equipment, net | $5.34B | $4.78B | $3.54B | $2.37B | $1.88B |
| Goodwill and intangible assets | $381.4M | $370.5M | $387.8M | $398.3M | $414.1M |
| Long-term investments | $3.3B | $5.06B | $2.12B | $2.62B | $4.42B |
| Total non-current assets | $10.9B | $11.7B | $7.55B | $6.72B | $7.71B |
| Total assets | $20.6B | $18.8B | $15.4B | $13B | $13.6B |
| Accounts payable | $255.1M | $193.4M | $188.7M | $147M | $121.2M |
| Short-term debt | $39M | $33.5M | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $506.7M | $468.8M | $446.1M | $397.3M | $377.2M |
| Total current liabilities | $2.01B | $1.75B | $1.66B | $1.42B | $1.15B |
| Long-term debt | $263.8M | $112.5M | $0.00 | $0.00 | $87M |
| Deferred revenue, non-current | $91.4M | $54.1M | $45.6M | $41M | $36.8M |
| Total non-current liabilities | $683.3M | $563.7M | $385.5M | $439.3M | $453.7M |
| Capital lease obligations | $131.9M | $112.5M | $0.00 | $0.00 | $87M |
| Total liabilities | $2.69B | $2.31B | $2.04B | $1.86B | $1.6B |
| Common stock | $400K | $400K | $400K | $400K | $400K |
| Retained earnings | $7.01B | $6.8B | $4.74B | $3.5B | $4.76B |
| Accumulated other comprehensive income (loss) | $43.3M | -$-51.3M | -$-12.2M | -$-162.5M | -$-24.2M |
| Total equity | $17.9B | $16.5B | $13.4B | $11.1B | $12B |
| Total investments | $5.87B | $7.05B | $4.59B | $5.16B | $7.36B |
| Total debt | $302.8M | $146M | $0.00 | $0.00 | $87M |
| Net debt | -$-3.07B | -$-1.88B | -$-2.75B | -$-1.58B | -$-1.2B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $2.88B | $2.34B | $1.82B | $1.34B | $1.73B |
| Depreciation and amortization | $677.1M | $462M | $435.2M | $365.8M | $310.2M |
| Stock-based compensation | $788.2M | $676.8M | $598.2M | $513.2M | $449.2M |
| Change in working capital | -$-1.27B | -$-919.3M | -$-777.6M | -$-619.1M | -$-368.1M |
| Accounts receivable | -$-301.7M | -$-95.9M | -$-186.3M | -$-159.3M | -$-142.3M |
| Inventory | -$-1.06B | -$-830M | -$-712.5M | -$-546.6M | -$-256M |
| Accounts payable | $57.9M | -$-400K | $41.7M | $21.3M | $36M |
| Net cash provided by operating activities | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Investments in property, plant and equipment | -$-539.8M | -$-1.11B | -$-1.06B | -$-532.4M | -$-353.5M |
| Acquisitions, net | -$-13.9M | -$-1M | -$-8.9M | -$-12.8M | -$-8.7M |
| Net cash used for investing activities | $665.8M | -$-3.27B | -$-360.1M | $1.37B | -$-2.46B |
| Common stock issued | $350.3M | $429.4M | $296.3M | $0.00 | $276.5M |
| Common stock repurchased | -$-2.3B | $0.00 | -$-416.3M | -$-2.61B | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-2.36B | $150.9M | -$-287.6M | -$-2.57B | $43M |
| Net change in cash | $1.35B | -$-707.7M | $1.17B | $294.7M | -$-332.5M |
| Cash at end of period | $3.41B | $2.06B | $2.77B | $1.6B | $1.31B |
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B |
| Capital expenditure | -$-539.8M | -$-1.11B | -$-1.06B | -$-532.4M | -$-353.5M |
| Free cash flow | $2.49B | $1.3B | $749.6M | $958.4M | $1.74B |
Line items
Line items
Line items
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
- CEO
- David J. Rosa
- Employees
- 17.02K
- Beta
- 1.46
Included in
Explore
Frequently asked questions
What is the intrinsic value of Intuitive Surgical, Inc. (ISRG)?
Intuitive Surgical, Inc. (ISRG) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ISRG undervalued?
ISRG trades at a price of $399.05 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.